Avid Bioservices Inc (CDMO)

[semper]

Allison Stopeck, MD

“The results of this Phase I breast cancer trial are encouraging as there were no new safety signals and excellent clinical responses,” said Alison Stopeck, MD, Associate Professor of Medicine and Director, Clinical Breast Cancer Program at the University of Arizona Cancer Center. “There were several laboratory correlative studies associated with the trial which confirmed the safety of bavituximab with regard to coagulation parameters.”
http://argyllfreepress.com/2013/06/03/peregrine-pharmaceuticals-nasdaqpphm-up-on-positive-results-of-bavituximab/

Who is Dr Alison Stopeck?

Alison Stopeck is a board certified Internist, Hematologist, and Medical Oncologist and Director of the Arizona Hemophilia and Thrombosis Center-Tucson and the Clinical Breast Cancer Program at the The University of Arizona Cancer Center. She received her medical doctorate from Columbia University College of Physicians and Surgeons. She then remained at Columbia, completing her residency in Internal Medicine at Columbia Presbyterian Medical Center. Her Fellowship in Hematology and Oncology was completed at Cornell University Medical College.

She currently holds the rank of Professor of Medicine at the University of Arizona. She has more than 50 publications in medical journals and textbooks, including the New England Journal of Medicine and the Journal of Clinical Oncology. She acts as an Associate Editor for the American Journal of Medicine and is an ad hoc reviewer for several journals. Memberships include the American Society of Clinical Oncology, the American Society of Hematology, the American Association of Cancer Research, and the Southwest Oncology Group. She has been named to the “Best Doctors in America”, “Best Doctors in Tucson”, and “Who’s Who in America, Professional Edition” on multiple occasions and has a very active clinical practice in breast cancer as well as bleeding and clotting disorders. Dr. Stopeck is the principle or collaborating investigator on multiple clinical trials involving novel agents, prognostic markers and predictors of response in breast cancer patients, as well as supportive care and survivorship issues in hemophilia and breast cancer.
http://azcc.arizona.edu/profile/alison-stopeck